Percivalle, E., Cambiè, G., Cassaniti, I., Nepita, E.V., Maserati, R., Ferrari, A., Di Martino, R., Isernia, P., Mojoli, F., Bruno, R., Tirani, M., Cereda, D., Nicora, C., Lombardo, M. and Baldanti, F. (2020) Prevalence of SARS-CoV-2 Specific Neutralising Antibodies in Blood Donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Eurosurveillance, 25, Article ID: 2001031,
https://doi.org/10.2807/1560-7917.ES.2020.25.24.2001031

has been cited by the following article:

• TITLE: Seroprevalence of SARS-CoV-2 among Blood Donors in the Republic of Congo

  AUTHORS: Serge Oscar Mokono, Edwige Paola Chancelle Louanga Nanitelamio, Chaldam Jespère Mbani, Aude Tabapika, Taty Taty, Nina Esther Ngoyi Née Ontsira, Donatien Moukassa

  KEYWORDS: Seroprevalence, Blood Donors, Anti IgM Antibody, Anti IgG Antibody, Antigen, SARS-CoV-2

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.12 No.4, December 30, 2022

  ABSTRACT: Corona Virus Disease 2019 (COVID-19) is a highly transmissible and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which erupted in Wuhan, China, in 2019 and has spread worldwide [1]. The objective of this study was to assess the seroprevalence of SARS-CoV-2 among blood donors in the Republic of Congo. Method: This is an analytical and cross-sectional study that was carried out during the period from July to December 2021. Biological analyses were performed with the serological tests n2019 rapid IgG/IgM from Beijing Diagreat Biotechnologies and antigen tests from Abbot using the serum for the detection of anti-SARS-Cov-2 antibodies and nasal mucus for the detection of SARS-Cov-2 antigens. Statistical analysis was performed using SPSS version 22. The Results: Out of 2553 donors recruited in our study, we observed a predominance of male sex with 86.1% or a ratio of 6.19, the age group of 18 - 30 years was dominant with 45.9%, family donation represented 59.2%, the dominant profession was workers with 46.9% and the dominant blood group was O Rh positive with 54%. The prevalence of anti-SRAS-CoV-2 antibodies and antigens were respectively 31.4% for anti-SRAS CoV-2 IgG antibodies, 36.7% for anti-SRAS CoV-2 IgM antibodies and 2.93% for SARS-CoV-2 antigen.